Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SI)

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SI) — VMCI valuation read

Across 120 indicators, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SI) lands at VMCI 64/100. The Healthcare sector median is 50, so the 14-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on T14.SI in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, T14.SI trades at 21.0x earnings, 17% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp. On Risk, net debt to EBITDA of -0.3x leaves covenant headroom for T14.SI on the trailing balance sheet.

T14.SI fell 1.7% over the trailing 7 days, with a -0.7% read on a 30-day basis.